Physician profile
Melissa C Corcoran
NPI 1114976032
$3,454.86
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,582 · 2020: $206 · 2021: $355 · 2022: $32.70 · 2023: $1,176 · 2024: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $614.23 | 2019-2023 | Cabometyx |
| Janssen Biotech, INC. | $239.82 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $231.06 | 2019-2024 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $224.69 | 2019-2021 | |
| Genentech USA, INC. | $179.27 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $169.54 | 2019-2023 | Opdivo |
| Pfizer INC. | $158.97 | 2019-2023 | |
| Celgene Corporation | $123.76 | 2019-2023 | Reblozyl, Pomalyst, Opdualag |
| Seagen INC. | $92.57 | 2019-2023 | Adcetris, Padcev |
| Janssen Scientific Affairs, LLC | $90.23 | 2019 | |
| Eisai INC. | $83.78 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $81.72 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.35 | 2019 | |
| Genzyme Corporation | $63.67 | 2019-2021 | |
| Rigel Pharmaceuticals, INC. | $63.52 | 2019-2023 | Tavalisse, Rezlidhia |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Corcoran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.